Does Lurbinectedin Increase Cancer Recurrence Risk?
No evidence shows lurbinectedin increases cancer recurrence risk. Approved as Zepzelca by the FDA in 2020 for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy, it targets the tumor's DNA repair mechanisms to halt cancer cell growth.[1][2] Clinical trials like the phase 3 ATLANTIS study and earlier phase 2 trials (e.g., PM14-501) measured progression-free survival (PFS) and overall survival (OS), with no signals of higher recurrence rates compared to standard chemotherapy.[3][4]
What Do Clinical Trial Data Show on Recurrence?
In the pivotal phase 2 trial (n=105 SCLC patients), median PFS was 5.3 months with lurbinectedin alone versus 3.4 months historically with topotecan, and OS was 13.4 months versus 8.6 months.[4] The ATLANTIS trial (n=632) confirmed similar PFS (4.0 vs. 3.9 months) when added to irinotecan, without excess disease recurrence post-treatment.[3] Recurrence risk is tied to SCLC's aggressive biology—90% recur within a year regardless of therapy—not lurbinectedin itself.[5]
What Side Effects Are Linked Instead?
Common adverse events include myelosuppression (neutropenia in 58%, anemia in 50%), fatigue (40%), and nausea (37%), but these are reversible and do not correlate with recurrence.[1][2] No trial data or post-marketing reports flag lurbinectedin as promoting tumor regrowth, unlike concerns with some immunotherapies that can cause hyperprogression in rare cases.[6]
How Does It Compare to Standard SCLC Treatments?
Lurbinectedin outperforms topotecan in PFS and OS with better tolerability, filling a gap for relapsed SCLC where recurrence is inevitable for most.[4] Unlike PARP inhibitors, which risk resistance-driven recurrence in BRCA-mutated cancers, lurbinectedin's transcription inhibition avoids such rebound effects.[7]
Any Long-Term Recurrence Studies or Warnings?
Follow-up data beyond 2 years remain limited due to SCLC's short survival (median 8-12 months), but no recurrence risk signals appear in real-world evidence or ongoing trials like LAGOON (NCT05164134).[8] FDA labeling and EMA approval include no such warnings.[1][2] Patients with platinum-resistant disease see response rates of 35-40%, delaying—not hastening—recurrence.[3]
Sources
[1]: FDA Zepzelca Label
[2]: EMA Lurbinectedin Summary
[3]: Trigo et al., Lancet Oncol 2021 (ATLANTIS trial)
[4]: Paz-Ares et al., Lancet Oncol 2019 (phase 2 trial)
[5]: NCCN SCLC Guidelines v2.2024
[6]: Kato et al., J Thorac Oncol 2017 (hyperprogression review)
[7]: Beck et al., Cancer Discov 2019 (mechanism)
[8]: ClinicalTrials.gov NCT05164134